Literature DB >> 28228556

Activation and Functional Specialization of Regulatory T Cells Lead to the Generation of Foxp3 Instability.

Zhongmei Zhang1,2, Wei Zhang1, Jie Guo1, Qianchong Gu1,2, Xueping Zhu1,2, Xuyu Zhou3,2.   

Abstract

Accumulating evidence suggests that Foxp3+ cells can downregulate the expression of Foxp3, but whether thymically derived regulatory T cells (tTregs; especially committed tTregs) are capable of downregulating Foxp3 expression and being reprogrammed into other T effector cells remains controversial. Using a novel tTreg lineage-tracing mouse line, we were able to label epigenetically stable Foxp3+ cells derived from the thymus and demonstrate that mature tTregs are stable under homeostatic conditions. However, TCR engagement and sequential functional specialization of tTregs led to the generation of Foxp3 instability and reprogramming into the Th lineage. We further demonstrated that the signal switch from IL-2 to ICOS during Treg activation induced Treg instability and reprogramming. By using a dual lineage tracing model, we demonstrated that effector Tregs can revert to central Tregs, and this reversion is associated with increasing Foxp3 stability in vivo.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28228556     DOI: 10.4049/jimmunol.1601409

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Thymus-derived Foxp3+ regulatory T cells upregulate RORγt expression under inflammatory conditions.

Authors:  Juhao Yang; Mangge Zou; Joern Pezoldt; Xuyu Zhou; Jochen Huehn
Journal:  J Mol Med (Berl)       Date:  2018-10-24       Impact factor: 4.599

Review 2.  Regulatory T cells in autoimmune disease.

Authors:  Margarita Dominguez-Villar; David A Hafler
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

3.  Reciprocal Regulation of Glycolysis-Driven Th17 Pathogenicity and Regulatory T Cell Stability by Cdc42.

Authors:  Khalid W Kalim; Jun-Qi Yang; Yuan Li; Yan Meng; Yi Zheng; Fukun Guo
Journal:  J Immunol       Date:  2018-02-12       Impact factor: 5.422

Review 4.  Treg programming and therapeutic reprogramming in cancer.

Authors:  Mariela A Moreno Ayala; Zehui Li; Michel DuPage
Journal:  Immunology       Date:  2019-04-29       Impact factor: 7.397

5.  Genetic Tools for Analyzing Foxp3+ Treg Cells: Fluorochrome-Based Transcriptional Reporters and Genetic Fate-Mapping.

Authors:  Mario Simonetti; Acelya Yilmazer; Karsten Kretschmer
Journal:  Methods Mol Biol       Date:  2023

Review 6.  Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.

Authors:  Prabhakaran Kumar; Shikha Saini; Saad Khan; Swarali Surendra Lele; Bellur S Prabhakar
Journal:  Cell Immunol       Date:  2018-09-29       Impact factor: 4.868

7.  DOCK8 enforces immunological tolerance by promoting IL-2 signaling and immune synapse formation in Tregs.

Authors:  Erin Janssen; Sudha Kumari; Mira Tohme; Sumana Ullas; Victor Barrera; Jeroen Mj Tas; Marcela Castillo-Rama; Roderick T Bronson; Shariq M Usmani; Darrell J Irvine; Thorsten R Mempel; Raif S Geha
Journal:  JCI Insight       Date:  2017-10-05

Review 8.  Mechanisms of exTreg induction.

Authors:  Vikas Saxena; Ram Lakhan; Jegan Iyyathurai; Jonathan S Bromberg
Journal:  Eur J Immunol       Date:  2021-05-27       Impact factor: 6.688

9.  Human regulatory T cells (Treg) and their response to cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-07-15

10.  Regulatory T Cells License Macrophage Pro-Resolving Functions During Atherosclerosis Regression.

Authors:  Monika Sharma; Martin P Schlegel; Milessa S Afonso; Emily J Brown; Karishma Rahman; Ada Weinstock; Brian E Sansbury; Emma M Corr; Coen van Solingen; Graeme J Koelwyn; Lianne C Shanley; Lauren Beckett; Daniel Peled; Juan J Lafaille; Matthew Spite; P'ng Loke; Edward A Fisher; Kathryn J Moore
Journal:  Circ Res       Date:  2020-04-27       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.